✉news HealthMedicine first seen 5 d ago, last 5 d ago, peak #23
FDA Grants Accelerated Approval to INOVIO's VOCERYQ for Recurrent Respiratory Papillomatosis
Original: INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
INOVIO says the US Food and Drug Administration has granted accelerated approval to VOCERYQ, an immunotherapy for adults with recurrent respiratory papillomatosis, a rare condition that causes recurring wart-like growths in the airway. The drug is approved to reduce how often patients need surgery to remove the growths. It marks a first approval for INOVIO, which has spent years developing DNA-based medicines without bringing a product to market.
Why now: It is INOVIO's first FDA-approved product, a milestone for the company and a new nonsurgical option for a rare disease.
INOVIOVOCERYQFDArecurrent respiratory papillomatosis
Evidence
API: https://socialmediatrends-api.osmike.com/v1/trends/4580885